The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer
Abstract
CEA is a complex glycoprotein produced by 90% of colorectal cancers and contributes to the malignant characteristics of a tumor. It can be measured in serum quantitatively, and its level in plasma can be useful as a marker of disease. Because of its lack of sensitivity in the early stages of colorectal cancer, CEA measurement is an unsuitable modality for population screening. An elevated preoperative CEA is a poor prognostic sign and correlates with reduced overall survival after surgical resection of colorectal carcinoma. A failure of the CEA to return to normal levels after surgical resection is indicative of inadequate resection of occult systemic disease. Frequent monitoring of CEA postoperatively may allow identification of patients with metastatic disease for whom surgical resection or other localized therapy might be potentially beneficial. To identify this group, serial CEA measurement appears to be more effective than clinical evaluation or any other diagnostic modality, although its sensitivity for detecting recurrent disease is not as high for locoregional or pulmonary metastases as it is for liver metastases. Several studies have shown that a small percentage of patients followed postoperatively with CEA monitoring and who undergo CEA-directed salvage surgery for metastatic disease will be alive and disease-free 5 years after surgery. Furthermore, CEA levels after salvage surgery do appear to predict survival in patients undergoing resection of liver or pulmonary metastases. However, several authors argue that CEA surveillance is not cost-effective in terms of lives saved. In support of this argument, there is no clear difference in survival after resection of metastatic disease with curative intent between patients in whom the second-look surgery was performed on the basis of elevated CEA levels and those with other laboratory or imaging abnormalities. There is also no clear consensus on the frequency or duration of CEA monitoring, although the ASCO guidelines currently recommend every 2-3 months for at least 2 years after diagnosis. In the follow-up of patients undergoing palliative therapy, the CEA level correlates well with response, and CEA is indicative of not only response but may also identify patients with stable disease for whom there is also a demonstrated benefit in survival and symptom relief with combination chemotherapy. More recently, scintigraphic imaging after administration of radiolabeled antibodies afforded an important radionuclide technique that adds clinically significant information in assessing the extent and location of disease in patients with colorectal cancer above and beyond or complementary to conventional imaging modalities. Immunotherapy based on CEA is a rapidly advancing area of clinical research demonstrating antibody and T-cell responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510350091047 · Cited by 1,791
Prognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999
Bostwick, D. G., Grignon, D. J., Hammond, M. E. H., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,239
Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement 1999
Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., Hammond, M. E. H., Henson, D. E., Hutter, R. V. P., Nagle, R. B., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0979-pficc · Cited by 1,230
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
Benchimol, S., Fuks, A., Jothy, S., Beauchemin, N., Shirota, K., & Stanners, C. P. (1989) · Cell · doi:10.1016/0092-8674(89)90970-7 · Cited by 974
Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history
Scheele, J., Stangl, R., & Altendorf-Hofmann, A. (1990) · Journal of British Surgery · doi:10.1002/bjs.1800771115 · Cited by 836
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Duffy, M. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.624 · Cited by 794
Factors influencing the natural history of colorectal liver metastases
Stangl, R., Altendorf-Hofmann, A., Charnley, R. M., & Scheele, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92529-1 · Cited by 722
FLETCHER, R. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-1-66 · Cited by 473
Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator in Colorectal Cancer
Wanebo, H. J., Rao, B., Pinsky, C. M., Hoffman, R. G., Stearns, M., Schwartz, M. K., & Oettgen, H. F. (1978) · New England Journal of Medicine · doi:10.1056/nejm197808312990904 · Cited by 468
Moertel, C. G. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080047030 · Cited by 449
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2843 · Cited by 353
Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment
Saito, Y., Omiya, H., Kohno, K., Kobayashi, T., Itoi, K., Teramachi, M., Sasaki, M., Suzuki, H., Takao, H., & Nakade, M. (2002) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2002.125165 · Cited by 330
Mäkelä, J. T. (1995) · Archives of Surgery · doi:10.1001/archsurg.1995.01430100040009 · Cited by 324
Follow-Up of Patients with Colorectal Cancer A Meta-Analysis
Bruinvels, D. J., Stiggelbout, A. M., Kievit, J., van Houwellngen, H. C., F. Habbema, J. D., & van de Velde, C. J. H. (1994) · Annals of Surgery · doi:10.1097/00000658-199402000-00009 · Cited by 322
Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study
MINTON, J. P., Hoehn, J. L., Gerber, D. M., Horsley, J. S., Connolly, D. P., Salwan, F. A., Fletcher, W. S., Cruz, A. B., Gatchell, F. G., Oviedo, M., et al. (1985) · Cancer · doi:10.1002/1097-0142(19850315)55:6<1284::aid-cncr2820550622>3.0.co;2-b · Cited by 252
Follow-up of patients with colorectal cancer
Kievit, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00061-8 · Cited by 206
Rothenberg, M. L., Cox, J. V., DeVore, R. F., Hainsworth, J. D., Pazdur, R., Rivkin, S. E., Macdonald, J. S., Geyer, C. E., Sandbach, J., Wolf, D. L., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9 · Cited by 201
Carcinoembryonic Antigen as a Selective Enhancer of Colorectal Cancer Metastasis
Hostetter, R. B., Augustus, L. B., Mankarious, R., Chi, K., Fan, D., Toth, C., Thomas, P., & Jessup, J. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.5.380 · Cited by 193
Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology
Desch, C. E., Benson, A. B., Smith, T. J., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., Petrelli, N. J., Pfister, D. G., & Somerfield, M. R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1312 · Cited by 193
Graham, R. A., Wang, S., Catalano, P. J., & Haller, D. G. (1998) · Annals of Surgery · doi:10.1097/00000658-199807000-00009 · Cited by 176
Figueras, J., Valls, C., Rafecas, A., Fabregat, J., Ramos, E., & Jaurrieta, E. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01821.x · Cited by 174
Sugarbaker, P. H., Gianola, F. J., Dwyer, A. A., & Neuman, N. (1987) · PubMed · Cited by 172
McCall, J. L., Black, R. B., Rich, C. A., Harvey, J. R., Baker, R. A., Watts, J. M., & Toouli, J. (1994) · Diseases of the Colon & Rectum · doi:10.1007/bf02052591 · Cited by 166
von Mehren, M., Arlen, P. M., Tsang, K. Y., Rogatko, A., Meropol, N. J., Cooper, H. S., Davey, M. P., McLaughlin, S. B., Schlom, J., & Weiner, L. M. (2000) · PubMed · Cited by 156
Conry, R. M., Curiel, D. T., Strong, T. V., Moore, S. E., Allen, K. O., Barlow, D. L., Shaw, D. R., & LoBuglio, A. F. (2002) · PubMed · Cited by 147
Foon, K., Chakraborty, M., John, W. J., et al. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118039 · Cited by 137
Zimmermann, W., Ortlieb, B., Friedrich, R., & von Kleist, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.2960 · Cited by 127
Surveillance after colorectal cancer resection
Berman, J. M., Cheung, R. J., & Weinberg, D. S. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06552-6 · Cited by 124
Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma?
Böhm, B., Schwenk, W., Hucke, H.-P., & Stock, W. G. (1993) · Diseases of the Colon & Rectum · doi:10.1007/bf02053511 · Cited by 115
Carcinoembryonic Antigen in Staging and Follow-Up of Patients with Solid Tumors
Ballesta, A. M., Molina, R., Filella, X., Jo, J., & Giménez, N. (1995) · Tumor Biology · doi:10.1159/000217926 · Cited by 111
Accuracy of Investigations for Asymptomatic Colorectal Liver Metastases
Glover, C., Douse, P., Kane, P., Karani, J. B., Meire, H. B., Mohammadtaghi, S., & Allen-Mersh, T. G. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6224-y · Cited by 110
CEA Monitoring Among Patients in Multi-institutional Adjuvant G.I. Therapy Protocols
Steele, G., ELLENBERG, S., Ramming, K. P., O’Connell, M. J., Moertel, C. G., Lessner, H. E., Bruckner, H. W., HORTON, J., SCHEIN, P., Zamcheck, N., et al. (1982) · Annals of Surgery · doi:10.1097/00000658-198208000-00008 · Cited by 109
Hohenberger, P., Schlag, P. M., Gerneth, T., & Herfarth, C. H. (1994) · Annals of Surgery · doi:10.1097/00000658-199402000-00005 · Cited by 108
Staab, H. J., Anderer, F. A., Stumpf, E., & Fischer, R. (1978) · The American Journal of Surgery · doi:10.1016/0002-9610(78)90285-4 · Cited by 102
Wiratkapun, S., Kraemer, M., Seow‐Choen, F., et al. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234298 · Cited by 89
Wood, C. B., Ratcliffe, J. G., Burt, R. W., Malcolm, A., & Blumgart, L. H. (1980) · British journal of surgery · doi:10.1002/bjs.1800670114 · Cited by 84
Kievit, J., & van de Velde, C. J. �. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2580::aid-cncr2820651131>3.0.co;2-i · Cited by 83
Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer
Mayer, R. J., Garnick, M. B., Steele, G. D., et al. (1978) · Cancer · doi:10.1002/1097-0142(197809)42:3+<1428::aid-cncr2820420808>3.0.co;2-h · Cited by 80
Carcinoembryonic antigen (CEA) in diagosis and prognosis of colorectal carcinoma
Arnaud, J., Koehl, C., & Adloff, M. (1980) · Diseases of the Colon & Rectum · doi:10.1007/bf02587615 · Cited by 78
Prognostic Significance of Carcinoembryonic Antigen in Colorectal Carcinoma
Chu, D. Z. J. (1991) · Archives of Surgery · doi:10.1001/archsurg.1991.01410270054010 · Cited by 73
Staab, H.-J., Anderer, F. A., Hornung, A., Stumpf, E., & Fischer, R. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.270 · Cited by 64
Tartter, P. I., SLATER, G., Gelernt, I. M., & Aufses, A. H. (1981) · Annals of Surgery · doi:10.1097/00000658-198103000-00019 · Cited by 58
Tobioka, H., Isomura, H., Kokai, Y., & Sawada, N. (2002) · The Journal of Pathology · doi:10.1002/path.1201 · Cited by 45
The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer
Hall, N. R., Finan, P. J., Stephenson, B., Purves, D. A., & Cooper, E. H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.343 · Cited by 39
Quentmeier, A., Schlag, P., Hohenberger, P., Schwarz, V., & Abel, U. R. (1989) · Journal of Surgical Oncology · doi:10.1002/jso.2930400211 · Cited by 35
Primus, F. J., Newman, E. S., & Hansen, H. J. (1977) · The Journal of Immunology · doi:10.4049/jimmunol.118.1.55 · Cited by 35
Kammerer, R., & von Kleist, S. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570309 · Cited by 34
Cost effectiveness of postoperative carcinoembryonic antigen monitoring in colorectal cancer
Sandler, R. S., Freund, D. A., Herbst, C. A., & Sandler, D. P. (1984) · Cancer · doi:10.1002/1097-0142(19840101)53:1<193::aid-cncr2820530134>3.0.co;2-v · Cited by 34
Detection of recurrent cancer of the colon and rectum
Graffner, H., Hultberg, B., Johansson, B., Müller, T., & Petersson, B. G. (1985) · Journal of Surgical Oncology · doi:10.1002/jso.2930280219 · Cited by 26
CEA Monitoring After Surgery for Colorectal Cancer: When Is the Evidence Sufficient?
Fletcher, R. H. (1993) · JAMA · doi:10.1001/jama.270.8.987 · Cited by 21
Cited by
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Shmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., St. Clair, R., Baljevic, M., White, I., Jin, D. K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34401 · Cited by 896
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., Tacey, M., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 635
Metadata
- Authors
- Goldstein, M. J., & Mitchell, E. P.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 23
- Issue
- 4
- Pages
- 338-351
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2083876596
- Cited by
- 419
- References
- 51
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.